{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:58:21Z","timestamp":1780333101596,"version":"3.54.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1038\/leu.2012.201","type":"journal-article","created":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T13:30:05Z","timestamp":1357738205000},"page":"1-2","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A window into immunoglobulin quantitation and plasma cell disease: antigen epitopes defined by the junction of immunoglobulin heavy and light chains"],"prefix":"10.1038","volume":"27","author":[{"given":"J A","family":"Katzmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S V","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,9]]},"reference":[{"key":"BFleu2012201_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV . Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3\u20139.","journal-title":"Leukemia"},{"key":"BFleu2012201_CR2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","volume":"47","author":"AR Bradwell","year":"2001","unstructured":"Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673\u2013680.","journal-title":"Clin Chem"},{"key":"BFleu2012201_CR3","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1182\/blood.V97.9.2900","volume":"97","author":"M Drayson","year":"2001","unstructured":"Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR . Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900\u20132902.","journal-title":"Blood"},{"key":"BFleu2012201_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/leu.2008.307","volume":"23","author":"A Dispenzieri","year":"2009","unstructured":"Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215\u2013224.","journal-title":"Leukemia"},{"key":"BFleu2012201_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2141.2007.06561.x","volume":"137","author":"MC Kyrtsonis","year":"2007","unstructured":"Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007; 137: 240\u2013243.","journal-title":"Br J Haematol"},{"key":"BFleu2012201_CR6","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1038\/leu.2010.128","volume":"24","author":"S Kumar","year":"2010","unstructured":"Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann JA, Snyder M et al. Relationship between elevated immunoglobulin free light chain and the presence of high translocations in multiple myeloma. Leukemia 2010; 24: 1498\u20131505.","journal-title":"Leukemia"},{"key":"BFleu2012201_CR7","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, Bradwell AR, Clark RJ et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS). Blood 2005; 106: 812\u2013817.","journal-title":"Blood"},{"key":"BFleu2012201_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","volume":"17","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering(asymptomatic)multiple myeloma. Blood 2008; 17: 785\u2013789.","journal-title":"Blood"},{"key":"BFleu2012201_CR9","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.4065\/81.12.1575","volume":"81","author":"JA Katzmann","year":"2006","unstructured":"Katzmann JA, Dispenzieri A, Kyle R, Snyder MR, Plevak MF, Larson DR et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 2006; 81: 1575\u20131578.","journal-title":"Mayo Clin Proc"},{"key":"BFleu2012201_CR10","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","volume":"55","author":"JA Katzmann","year":"2009","unstructured":"Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009; 55: 1517\u20131522.","journal-title":"Clin Chem"},{"key":"BFleu2012201_CR11","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1373\/clinchem.2011.163766","volume":"57","author":"LJ Donato","year":"2011","unstructured":"Donato LJ, Zeldenrust SR, Murray DL, Katzmann JAA . 71-year-old woman with multiple myeloma status after stem cell transplantation. Clin Chem 2011; 57: 1645\u20131648.","journal-title":"Clin Chem"},{"key":"BFleu2012201_CR12","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1373\/clinchem.2009.123828","volume":"55","author":"AR Bradwell","year":"2009","unstructured":"Bradwell AR, Harding SJ, Fourrier NJ, Wallis GL, Drayson MT, Carr-Smith HD et al. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa\/lambda ratios. Clin Chem 2009; 55: 1646\u20131655.","journal-title":"Clin Chem"},{"key":"BFleu2012201_CR13","doi-asserted-by":"crossref","unstructured":"Ludwig H, Milosavljevic D, Zojer N, Faint JM, Bradwell AR, H\u00fcbl W et al. Immunoglobulin heavy\/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia 2012, (this issue).","DOI":"10.1038\/leu.2012.197"},{"key":"BFleu2012201_CR14","doi-asserted-by":"crossref","unstructured":"Bradwell A, Harding S, Fourrier N, Mathiot C, Attal M, Moreau P et al. Prognostic utility of intact immunoglobulin Ig\u2019\u03ba\/ Ig\u2019\u03bb ratios in multiple myeloma patients. Leukemia 2012, (this issue).","DOI":"10.1038\/leu.2012.159"},{"key":"BFleu2012201_CR15","doi-asserted-by":"crossref","unstructured":"Katzmann JA, Clark R, Kyle RA, Larson DR, Therneau TM, Melton LJ et al. Suppression of uninvolved immunoglobulins defined by heavy\/light-chain pair suppression is a risk factor for progression of MGUS. Leukemia 2012, (this issue).","DOI":"10.1038\/leu.2012.189"},{"key":"BFleu2012201_CR16","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1038\/leu.2010.190","volume":"24","author":"MQ Lacy","year":"2010","unstructured":"Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010; 24: 1934\u20131939.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2012201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012201","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T10:08:33Z","timestamp":1654855713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2012201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["BFleu2012201"],"URL":"https:\/\/doi.org\/10.1038\/leu.2012.201","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"9 January 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Katzmann has received travel funds from The Binding Site, the manufacturer of the Hevylite assay. The authors declare no other conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}